Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

Frontiers Therapeutic targeting of leukemia stem cells in acute

National Cancer Institute (NCI) on LinkedIn: #melanoma

Cancer Currents: An NCI Cancer Research Blog - NCI

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant

Namrata Gautam on LinkedIn: Signals released from dying cancer

Therapeutic implications of menin inhibition in acute leukemias

Effective Menin inhibitor-based combinations against AML with MLL

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant

I-131 apamistamab induces response among adults with advanced